Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. / Bloch, Sara Brandi; la Cour, Morten; Sander, Birgit; Hansen, Louise K H; Fuchs, Josefine; Lund-Andersen, Henrik; Larsen, Michael.

In: Acta Ophthalmologica, 2013.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Bloch, SB, la Cour, M, Sander, B, Hansen, LKH, Fuchs, J, Lund-Andersen, H & Larsen, M 2013, 'Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment', Acta Ophthalmologica. https://doi.org/10.1111/j.1755-3768.2011.02268.x

APA

Bloch, S. B., la Cour, M., Sander, B., Hansen, L. K. H., Fuchs, J., Lund-Andersen, H., & Larsen, M. (2013). Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmologica. https://doi.org/10.1111/j.1755-3768.2011.02268.x

Vancouver

Bloch SB, la Cour M, Sander B, Hansen LKH, Fuchs J, Lund-Andersen H et al. Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. Acta Ophthalmologica. 2013. https://doi.org/10.1111/j.1755-3768.2011.02268.x

Author

Bloch, Sara Brandi ; la Cour, Morten ; Sander, Birgit ; Hansen, Louise K H ; Fuchs, Josefine ; Lund-Andersen, Henrik ; Larsen, Michael. / Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment. In: Acta Ophthalmologica. 2013.

Bibtex

@article{f19cb859d0444ba4ab4aa2130f4e19a7,

title = "Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment",

abstract = "Purpose: To describe predictors of visual outcome in patients treated with intravitreal ranibizumab for choroidal neovascularisation (CNV) in age-related macular degeneration (AMD). Methods: Retrospective review of 279 patients with CNV in AMD who fulfilled MARINA/ANCHOR study eligibility criteria and were treated with repeated intravitreal injections of ranibizumab 0.5 mg in routine clinical practice, beginning with three initial injections at 4-week intervals followed by individualized retreatment for the subsequent 9 months. Study parameters included best-corrected visual acuity (BCVA) and morphological characteristics. Results: Mean BCVA relative to baseline was +4.7 (p 0.667) Early Treatment Diabetic Retinopathy Study letters after 3, 6 and 12 months, respectively, after a mean of 5.1 injections when the proportion of patients with BCVA =70 letters had doubled compared with baseline. Predictive factors for BCVA =35 letters after 12 months were BCVA =35 letters at baseline and month 3 (p ",

author = "Bloch, {Sara Brandi} and {la Cour}, Morten and Birgit Sander and Hansen, {Louise K H} and Josefine Fuchs and Henrik Lund-Andersen and Michael Larsen",

note = "{\textcopyright} 2011 The Authors. Acta Ophthalmologica {\textcopyright} 2011 Acta Ophthalmologica Scandinavica Foundation.",

year = "2013",

doi = "10.1111/j.1755-3768.2011.02268.x",

language = "English",

journal = "Acta Ophthalmologica",

issn = "1755-375X",

publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment

AU - Bloch, Sara Brandi

AU - la Cour, Morten

AU - Sander, Birgit

AU - Hansen, Louise K H

AU - Fuchs, Josefine

AU - Lund-Andersen, Henrik

AU - Larsen, Michael

PY - 2013

Y1 - 2013

N2 - Purpose: To describe predictors of visual outcome in patients treated with intravitreal ranibizumab for choroidal neovascularisation (CNV) in age-related macular degeneration (AMD). Methods: Retrospective review of 279 patients with CNV in AMD who fulfilled MARINA/ANCHOR study eligibility criteria and were treated with repeated intravitreal injections of ranibizumab 0.5 mg in routine clinical practice, beginning with three initial injections at 4-week intervals followed by individualized retreatment for the subsequent 9 months. Study parameters included best-corrected visual acuity (BCVA) and morphological characteristics. Results: Mean BCVA relative to baseline was +4.7 (p 0.667) Early Treatment Diabetic Retinopathy Study letters after 3, 6 and 12 months, respectively, after a mean of 5.1 injections when the proportion of patients with BCVA =70 letters had doubled compared with baseline. Predictive factors for BCVA =35 letters after 12 months were BCVA =35 letters at baseline and month 3 (p

AB - Purpose: To describe predictors of visual outcome in patients treated with intravitreal ranibizumab for choroidal neovascularisation (CNV) in age-related macular degeneration (AMD). Methods: Retrospective review of 279 patients with CNV in AMD who fulfilled MARINA/ANCHOR study eligibility criteria and were treated with repeated intravitreal injections of ranibizumab 0.5 mg in routine clinical practice, beginning with three initial injections at 4-week intervals followed by individualized retreatment for the subsequent 9 months. Study parameters included best-corrected visual acuity (BCVA) and morphological characteristics. Results: Mean BCVA relative to baseline was +4.7 (p 0.667) Early Treatment Diabetic Retinopathy Study letters after 3, 6 and 12 months, respectively, after a mean of 5.1 injections when the proportion of patients with BCVA =70 letters had doubled compared with baseline. Predictive factors for BCVA =35 letters after 12 months were BCVA =35 letters at baseline and month 3 (p

U2 - 10.1111/j.1755-3768.2011.02268.x

DO - 10.1111/j.1755-3768.2011.02268.x

M3 - Journal article

C2 - 22008284

JO - Acta Ophthalmologica

JF - Acta Ophthalmologica

SN - 1755-375X

ER -

ID: 40149354

Forskning